Originally addressing complications of diabetes and aging, engaging technology licensed from Fox Chase Cancer Center and involving several personnel from that establishment, Dynamis Therapeutics, Inc. organzied around developing new drugs to treat chronic inflammatory disease. The underlying concept was that of lowering the levels of 3-deoxyglucosone. Products include DYN 15, a drug candidate that prevents the formation of 3DG, a highly reactive sugar, as well as lowers the levels of several key cytokines that are stimulated in chronic inflammations. The company's products also include an enzymatic pathway that causes chronic inflammation; and MEG 21, an anti-aging treatment product for face treatment, hand treatment, eye treatment, anti-oxidant boosting, and redness relief. The firm's proprietary drug candidates inhibit a novel enzymatic pathway that causes the formation of a highly reactive sugar, 3-deoxyglucosone, that stimulates the production of Advanced Glycation End Products (AGEs), oxidative stress and a cascade of inflammatory cytokines.